Clinical Trial Search Results

Click on the name (title) to see the trial details in the LRG database. You will also have the opportunity to access trial site data later. Trials are sorted so that trials that are only for GIST appear first. Trials are also sorted so that trials in later phases sort higher on the list. The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database.

6 trials found

Temodar

Temozolomide in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors
Phase:   2
 
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: First-line
Status:  Completed
Site
City
State
Country


Temodar

Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor
Phase:   2
 
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: Gleevec-resistant
Status:  Recruiting
Site
City
State
Country
Moores Cancer Center/UCSD Medical center La Jolla CA USA


Guadecitabine

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer
Phase:   2
 
Drug Category:  SDH-directed
Conditions: SDH- GIST
Treatment Phase: First-line
Status:  Recruiting
Site
City
State
Country
Naytional Cancer Institute Bethesda MD USA


Telaglenastat

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Phase:   1
 
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Active, not recruiting
Site
City
State
Country
MD Anderson Cancer Center Houston TX USA
University of Pennsylvania Philadelphia PA USA
Memorial Sloan-Kettering Cancer Center New York NY USA
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA USA
Stanford University Medical Center Palo Alto CA USA
Florida Cancer Specialists Sarasota FL USA
Tennessee Oncology Nashville TN USA
Emory Winship Cancer Institute Atlanta GA USA
Dana Farber Cancer Institute Boston MA USA
Beth Israel Deaconess Medical Center Boston MA USA
Massachusetts General Hospital Boston MA USA
Columbia University - Herbert Irving Cancer Center New York NY USA
Naytional Cancer Institute Bethesda MD USA


Telaglenastat + Talazoparib

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Phase:   1/2
 
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Recruiting
Site
City
State
Country
South Texas Accelerated Research Therapeutics (START) San Antonio TX USA


CPI-613

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Phase:   2
 
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Terminated
Site
City
State
Country
Eastchester Center for Cancer Bronx NY USA


6 trials found